Combination of TRAIL-MSCs with BTZ causes synergistic cell death of classic and patient-derived neuroblastoma cell lines. (A) MSCs infected with a TRAIL lentivirus, or parental cells, were subjected to flow cytometric analysis with a TRAIL antibody. Cell death assays; (B) classic or (C) patient-derived neuroblastoma cell lines were cultured in the presence or absence of recombinant TRAIL (r-TRAIL), BTZ, mesenchymal stem cells engineered to express secreted TRAIL (TRAIL-MSCs) or their combinations. Error bars indicate the standard errors of the means of three (Kelly and SKNAS) or two (primary cell lines) experiments. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. MSCs, mesenchymal stem cells; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand; BTZ, Bortezomib.